Affinage

TFDP1

Transcription factor Dp-1 · UniProt Q14186

Length
410 aa
Mass
45.1 kDa
Annotated
2026-06-10
86 papers in source corpus 37 papers cited in narrative 36 extracted findings
Cross-family judge vs UniProt: tie faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TFDP1 (DP-1) is the sequence-specific DNA-binding subunit of the DRTF1/E2F transcription factor and functions as an obligate heterodimerization partner for E2F proteins to drive transcription of genes required for G1/S cell cycle progression (PMID:8405995, PMID:8446173, PMID:8223441). DP-1 was purified as a major DNA-binding component of E2F complexes whose DNA-binding domain recognizes E2F sites, and its heterodimerization with E2F-1 cooperatively enhances both DNA binding and trans-activation while also being required for stable binding to the pRb pocket protein, which represses heterodimer activity (PMID:8405995, PMID:8446173, PMID:8223441). Active E2F/DP-1 complexes are required for proliferation: dominant-negative DP-1 mutants that dimerize but cannot bind DNA arrest cells in G1, and DP-1 loss downregulates cell cycle effectors and target genes such as cyclins A and E, CDK2, and CCNE1 (PMID:8668186, PMID:8780882, PMID:12029633, PMID:14618416). DP-1 stability and nuclear localization depend on E2F association — DP-1 unable to bind E2F accumulates in the cytoplasm as polyubiquitinated protein subject to proteasomal degradation, and nuclear import of the E2F1/TFDP1 complex is mediated by KPNA2 (PMID:9989809, PMID:31783876). Heterodimer activity is further modulated by cell cycle phosphorylation and by an array of binding partners including p53 (which competes with E2F-1 for DP-1), TRIP-Br1, SOCS-3, COMMD9, and the adenoviral E4 ORF6/7 and E1A proteins (PMID:8039504, PMID:7969176, PMID:8816502, PMID:11331592, PMID:18687693, PMID:27871936, PMID:8035503, PMID:7933066, PMID:21715488). Beyond canonical cell cycle control, TFDP1 is itself a transcriptional target of deregulated E2F1 forming a feedback loop, modulates global chromatin accessibility through regulation of canonical histone genes, partners with E2F4 to sustain hematopoietic stem/progenitor cell proliferation, and recruits chromatin modifiers (BRG1, KDM6B) to specific promoters during developmental and regenerative programs (PMID:37141667, PMID:38361031, PMID:39043964, PMID:34746136, PMID:35212626). Recurrent and somatic TFDP1 mutations in human tumors alter DNA binding, transactivation, and pRb-binding properties of the heterodimer, with both transdominant loss and gain-of-function consequences for proliferation (PMID:23934193, PMID:25133581).

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 1993 High

    Established that DP-1 is the DNA-binding partner of E2F and that the two cooperate, answering how E2F achieves high-affinity, sequence-specific promoter binding and transactivation.

    Evidence Protein purification from E2F DNA-affinity columns, co-IP in vivo and in vitro, EMSA, and reporter trans-activation assays across mammalian, yeast, and Drosophila systems

    PMID:8223441 PMID:8405995 PMID:8446173

    Open questions at the time
    • Did not resolve the structural basis of cooperative DNA binding
    • Did not define which E2F family members preferentially partner DP-1 in vivo
  2. 1993 High

    Showed DP-1 heterodimerization is required for stable pRb binding, linking the heterodimer to growth-suppressive pocket-protein control.

    Evidence Co-IP and reporter assays demonstrating pRb inhibition of E2F-1/DP-1 trans-activation

    PMID:8405995

    Open questions at the time
    • Did not map the precise pRb-contact residues of DP-1 at this stage
  3. 1994 High

    Defined DP-1 as a cell cycle-regulated phosphoprotein and located the pRb- and viral-protein-contact regions, clarifying how heterodimer activity is gated.

    Evidence Cell fractionation, phosphorylation mobility-shift analysis, deletion-mutant co-IP and EMSA; cyclin A/CDK2 kinase assays on E2F-1

    PMID:7969176 PMID:8039504

    Open questions at the time
    • Kinase phosphorylating DP-1 itself not identified
    • Functional consequence of DP-1 phosphorylation not fully resolved
  4. 1992 Medium

    Showed cyclin A recruits CDK2 (p33cdk2) to the DRTF1/E2F complex, providing a route by which the heterodimer is coupled to cell cycle kinase activity.

    Evidence Fusion-protein binding assays, histone H1 kinase assay, and co-IP

    PMID:1297652

    Open questions at the time
    • Single-lab in vitro reconstitution
    • Did not establish in vivo kinetics or substrate specificity within the complex
  5. 1995 Medium

    Demonstrated that E2F-1/DP-1 co-overexpression drives premature S-phase entry and apoptosis with p53 accumulation, establishing the heterodimer as a coupled proliferation/death switch.

    Evidence Inducible and overexpression systems in myeloid cells with flow cytometry, Western blotting, and apoptosis assays

    PMID:8524253 PMID:8780882

    Open questions at the time
    • DP-1 alone insufficient — the DP-1-specific contribution to apoptosis not isolated
    • Single-lab models
  6. 1996 High

    Proved active E2F/DP-1 complexes are obligatory for cell cycle progression by showing DNA-binding-dead DP-1 arrests cells in G1, rescuable by wild-type protein.

    Evidence Dominant-negative DP-1 mutant transfection, flow cytometry, and domain mapping with rescue

    PMID:8668186

    Open questions at the time
    • Did not identify which endogenous target genes are most rate-limiting for arrest
  7. 1996 Medium

    Identified p53 as a direct DP-1 partner that competes with E2F-1, revealing crosstalk between the E2F and p53 programs at the level of DP-1.

    Evidence Co-IP in vivo and in vitro, competitive binding, deletion mapping, and reporter assays

    PMID:8816502

    Open questions at the time
    • Single-lab finding
    • Physiological stoichiometry of p53 vs E2F-1 competition for DP-1 not established
  8. 1999 Medium

    Explained how DP-1 abundance and localization are controlled — E2F association licenses nuclear entry, while unbound DP-1 is polyubiquitinated and degraded in the cytoplasm.

    Evidence Immunolocalization, co-IP, cell fractionation, and conditional expression with proteasome readouts

    PMID:9989809

    Open questions at the time
    • E3 ligase responsible for DP-1 ubiquitination not identified
    • Single-lab study
  9. 2010 Low

    Mapped a C-terminal acidic 'Stabilon' domain that protects DP-1 from proteasomal turnover, refining the determinants of DP-1 stability.

    Evidence Deletion-mutant analysis with Western blot and proteasome inhibitors

    PMID:20513349

    Open questions at the time
    • No in vitro reconstitution and no ligase identified
    • Single-lab deletion analysis only
  10. 2008 Medium

    Identified additional modulators (TRIP-Br1/2 stimulatory, SOCS-3 inhibitory) acting on DP-1, expanding the regulatory network controlling heterodimer activity.

    Evidence Yeast two-hybrid, co-IP, confocal co-localization, reporter assays, and siRNA

    PMID:11331592 PMID:18687693

    Open questions at the time
    • Single-lab interactions
    • Endogenous regulatory significance under physiological conditions not established
  11. 2011 Medium

    Showed adenoviral E1A (13S) and E4 ORF6/7 directly bind DP-1 to commandeer E2F-regulated transcription independent of pRb, defining a viral hijack mechanism through the DP-1 subunit.

    Evidence Co-IP, ChIP, reporter assays, and mutant viral constructs

    PMID:21715488 PMID:8035503

    Open questions at the time
    • Single-lab mechanism
    • Relevance to native E2F target selection not fully mapped
  12. 2013 Medium

    Connected TFDP1 to human cancer by cataloguing somatic mutations that preserve dimerization but alter DNA binding, transactivation, and pRb binding via a transdominant mechanism.

    Evidence Genomic mining with functional DNA-binding, transcription, pRb-binding, and apoptosis assays on mutant constructs

    PMID:23934193

    Open questions at the time
    • Causality in tumorigenesis not demonstrated in vivo
    • Single-lab functional series
  13. 2016 Medium

    Identified COMMD9 and additional partners enhancing TFDP1/E2F1 activity, and demonstrated direct TFDP1-driven transcription of specific developmental targets such as PITX1.

    Evidence Co-IP, siRNA, ChIP, and reporter/cell cycle assays in NSCLC and chondrocytes

    PMID:27802335 PMID:27871936

    Open questions at the time
    • Single-lab co-IP for each partner
    • Mechanism of COMMD9 stimulation not structurally defined
  14. 2019 Medium

    Established KPNA2 as the nuclear import factor for the E2F1/TFDP1 complex, linking subcellular trafficking to downstream target expression (STMN1) and tumor cell behavior.

    Evidence Co-IP, subcellular fractionation, ChIP, LC-MS/MS proteomics, siRNA, and colony assays in HCC cells

    PMID:31783876

    Open questions at the time
    • Single-lab study
    • Generalizability of KPNA2 dependence across cell types not tested
  15. 2022 Medium

    Showed TFDP1 recruits chromatin modifiers (KDM6B, and earlier BRG1 via E2F5) to specific promoters, extending DP-1's role to epigenetic control of target loci such as Trp53 and MYCN.

    Evidence Conditional knockout mouse, ChIP, co-IP, and reporter assays

    PMID:34746136 PMID:35212626

    Open questions at the time
    • Single-lab studies
    • Whether modifier recruitment is a general DP-1 property or locus-specific not resolved
  16. 2024 High

    Defined a broad genome-scale role for TFDP1 in setting global chromatin accessibility through canonical histone gene regulation, and confirmed its essentiality for HSPC proliferation via E2F4 partnership.

    Evidence Genome-wide CRISPR screen with ATAC-see/ATAC-seq; in vivo CRISPR screen, transplantation, and ChIP target identification

    PMID:38361031 PMID:39043964

    Open questions at the time
    • Causal chain from histone gene output to accessibility changes not fully dissected
    • Tissue specificity of the E2F4 vs other E2F partnerships not mapped
  17. 2025 Low

    Extended TFDP1 to tumor-promoting programs including transcription of TK1, SPC25, and suppression of senescence, positioning it as a candidate therapeutic target.

    Evidence ChIP, reporter, rescue, CRISPR library screens, and xenograft assays across cervical, lung, and triple-negative breast cancer models

    PMID:37715794 PMID:40300683 PMID:40552366

    Open questions at the time
    • Several are single-lab or limited functional validation
    • Molecular link between TFDP1 and senescence not fully resolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • The E3 ligase and full machinery controlling DP-1 ubiquitination/turnover, the structural basis of cooperative DNA binding, and the determinants of E2F partner choice across tissues remain unresolved.
  • No identified E3 ligase for cytoplasmic DP-1 degradation
  • No high-resolution structure of the DP-1/E2F/DNA complex in the corpus
  • Rules governing which E2F (E2F1 vs E2F4 vs E2F5) partners DP-1 in a given context unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 5 GO:0003677 DNA binding 4 GO:0060090 molecular adaptor activity 3
Localization
GO:0005654 nucleoplasm 3 GO:0005634 nucleus 2 GO:0005829 cytosol 2
Pathway
R-HSA-1640170 Cell Cycle 4 R-HSA-4839726 Chromatin organization 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1643685 Disease 2
Partners
COMMD9E2F1E2F4KDM6BKPNA2RB1SOCS3TP53
Complex memberships
DRTF1/E2F complexE2F1/DP-1 heterodimerE2F4/TFDP1 complexE2F5-TFDP1-BRG1 complex

Evidence

Reading pass · 36 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1993 DP-1 (TFDP1) and E2F-1 heterodimerize both in vivo and in vitro, enhancing binding to E2F DNA-binding sites and leading to cooperative trans-activation of E2F-responsive promoters. This heterodimerization is also required for stable interaction with pRb in vivo, and pRb inhibits trans-activation by E2F-1/DP-1 heterodimers. Co-immunoprecipitation (in vivo), in vitro binding assay, reporter gene trans-activation assays Genes & development High 8405995
1993 DP-1 is a major sequence-specific DNA-binding protein component of DRTF1/E2F, present in Rb- and p107-associated forms. Its DNA-binding domain resembles that of E2F-1 and recognizes the same sequence. Protein purification from E2F DNA-affinity column, cDNA isolation, DNA binding assays Nature High 8446173
1993 DP-1 and E2F-1 exist in a DNA-binding complex in vivo, binding efficiently and preferentially as a heterodimer to the E2F site, and interact synergistically in E2F site-dependent transcriptional activation in yeast and Drosophila cells. Co-immunoprecipitation, EMSA, transcription assays in yeast and Drosophila The EMBO journal High 8223441
1994 DP-1 is a phosphoprotein that undergoes a phosphorylation-dependent mobility shift during cell cycle progression. A C-terminal region of DP-1 interacts with pRb and, in the context of the DP-1/E2F-1 heterodimer, contributes to the efficiency of pRb binding. The DP-1/E2F-1 heterodimer specifically interacts with adenovirus type 5 E4 orf 6/7 protein to produce a cooperative DNA-binding activity. Cell fractionation, phosphorylation analysis, co-immunoprecipitation, EMSA, deletion mutant binding assays The EMBO journal High 8039504
1994 Cyclin A/CDK2 directly binds E2F-1 (but not DP-1) and phosphorylates E2F-1 in vitro and in vivo, inhibiting the DNA-binding activity of the E2F-1/DP-1 complex. The cyclin A/CDK2-binding region resides within the N-terminal 124 amino acids of E2F-1. In vitro kinase assay, co-immunoprecipitation, 2D tryptic phosphopeptide mapping, deletion mutant binding, DNA binding assay Molecular and cellular biology High 7969176
1994 Heterodimerization of E2F-1 and DP-1 is required for stable binding to adenovirus E4 (ORF6/7) protein. This binding is DNA-independent and requires the C-terminal 20 amino acids of E4 and a region of E2F-1 between amino acids 284 and 358. Importantly, pRb binding to the E2F-1/DP-1 heterodimer prevents formation of the E2F-1/DP-1/E4 complex, and the same internal segments of E2F-1 and DP-1 are required for both E4-6/7 and Rb binding. Co-immunoprecipitation, deletion mutant binding assays Journal of virology High 7933066 8035503
1992 Cyclin A recruits the CDK subunit p33cdk2 to the DRTF1/E2F transcription factor complex (which contains DP-1), activating histone H1 kinase activity within the complex. Cyclin A cannot direct p34cdc2 to the DRTF1 complex. Biologically active fusion protein binding assays, histone H1 kinase assay, co-immunoprecipitation Journal of cell science. Supplement Medium 1297652
1995 Co-expression of DP-1 and E2F-1 results in greater loss of G1 regulation and significantly more apoptosis than E2F-1 alone. Induction of E2F-1/DP-1 resulted in increased expression and activity of cyclins A and E, as well as CDK2, prior to S-phase entry; cyclin D and CDK4 were not induced. E2F-1/DP-1 also increases pRb phosphorylation, suggesting a feedback on pRb. Inducible expression system, flow cytometry, Western blotting, kinase assays, apoptosis assays Cell growth & differentiation Medium 8780882
1995 E2F-1:DP-1 co-overexpression overrides survival factor (IL-3) signaling to trigger rapid apoptosis, and augments p53 levels. DP-1 alone is insufficient to induce cell cycle progression or alter death rates, but cooperates with E2F-1 to induce apoptosis and p53 accumulation. Overexpression in IL-3-dependent myeloid cells, flow cytometry, Western blotting, apoptosis assays Molecular and cellular biology Medium 8524253
1996 Expression of dominant-negative DP-1 mutants that retain E2F dimerization but lack DNA binding arrests cells in G1, forming transcriptionally inactive E2F complexes. This G1 arrest can be rescued by co-expression of wild-type E2F or DP protein, establishing that active E2F/DP-1 complexes are required for cell cycle progression. Dominant-negative DP-1 mutant transfection, flow cytometry, domain mapping Molecular and cellular biology High 8668186
1996 DP-1 directly associates with p53 in mammalian cell extracts. In vitro, p53 interacts with an immunochemically distinct form of DP-1. p53 competes with E2F-1 for DP-1, reducing DNA-binding activity. A C-terminal region of DP-1 is required for p53 interaction; a distinct N-terminal region of p53 (different from MDM2-binding region) mediates this. Co-immunoprecipitation in vivo and in vitro, competitive binding assays, deletion mutant analysis, reporter assays Molecular and cellular biology Medium 8816502
1995 A Drosophila DP protein interacts co-operatively with E2F proteins as a physiological DNA-binding component of Drosophila DRTF1/E2F. The DRTF1/E2F pathway features (interaction with pocket proteins, binding to cyclin A and cdk2, modulation by viral oncoproteins) are conserved in Drosophila. Co-immunoprecipitation, DNA binding assay, transcriptional assays in Drosophila cells Journal of cell science Medium 8537434
1999 Association with E2F subunits governs intracellular trafficking and polyubiquitination of DP-1. DP-1 mutants that stably bind E2F-1 enter the nucleus, whereas DP-1 proteins that fail to associate with E2F accumulate in the cytoplasm as polyubiquitinated DP-1, subject to proteasomal degradation. Immunolocalization, co-immunoprecipitation, cell fractionation, transient transfection, conditional expression cell line Oncogene Medium 9989809
2001 TRIP-Br1/TRIP-Br2 proteins interact with DP-1 (similar to MDM2's homologous transactivation domain), stimulating E2F-1/DP-1 transcriptional activity. TRIP-Br1 is a component of a multiprotein complex containing E2F-1 and DP-1. Co-expression of Rb abolishes this co-activation, which is restored by adenovirus E1A. Yeast two-hybrid, co-immunoprecipitation, reporter assays, cell fractionation The EMBO journal Medium 11331592
2003 Loss of protein phosphatase 2A (PP2A) expression correlates with the appearance of a phosphorylated, slower-mobility form of DP-1 associated with cellular differentiation and reversal of dysplasia. Persistent PP2A expression prevents the phosphorylated form of DP-1 required for differentiation. Conditional mouse model, Western blot mobility shift analysis, immunohistochemistry Cancer research Low 14633688
2004 DP-1 activity is required for normal epidermal morphogenesis and keratinocyte growth. Expression of dominant-negative DP-1 (dnDP-1) inhibits E2F/DP-1 heterodimer DNA binding, blocks DNA replication, decreases cyclin A expression, and disrupts epidermal stratification. Chromatin immunoprecipitation showed the cyclin A promoter is bound by E2F-3/E2F-4-containing DP-1 complexes in proliferating keratinocytes. Dominant-negative expression, organotypic culture, embryonic ectoderm explants, ChIP, Western blotting The Journal of biological chemistry Medium 15448153
2005 Two novel DP-1 isoforms (DP-1α, DP-1β) were identified. DP-1α lacks a portion of the C-terminal heterodimerization domain, has significantly reduced E2F-1 binding, fails to translocate to the nucleus with E2F-1, and acts as a dominant-negative regulator of cell cycle progression, decreasing E2F transcriptional activity and inhibiting cell proliferation. Yeast two-hybrid, co-immunoprecipitation, immunofluorescence, reporter assays, flow cytometry The Journal of biological chemistry Medium 15863509
2008 SOCS-3 interacts with the C-terminal region of DP-1 (residues 156–172 of SOCS-3 required); they co-localize primarily in the cytoplasm. SOCS-3 inhibits E2F/DP-1 transcriptional activity and cell cycle progression by interfering with DP-1/E2F heterodimer formation. Reciprocally, DP-1 inhibits SOCS-3-mediated suppression of JAK-STAT signaling. Yeast two-hybrid, co-immunoprecipitation, confocal microscopy, reporter assays, siRNA knockdown The Journal of biological chemistry Medium 18687693
2010 A C-terminal acidic 'Stabilon' domain of DP-1 is critical for protein stability; removal of this domain leads to degradation. Wild-type DP-1 is degraded by the ubiquitin-proteasome system, and the Stabilon is identified as key for preventing this degradation. Deletion mutant analysis, Western blotting, proteasome inhibitor assays Biochemical and biophysical research communications Low 20513349
2011 Adenovirus E1A 13S isoform directly binds DP-1 (not pRb) to activate E2F-responsive gene expression. E1A recruits itself to E2F-regulated promoters through this direct DP-1 interaction, and E1A 13S (but not 12S) significantly enhances E2F4 occupancy at E2F sites. Co-immunoprecipitation, chromatin immunoprecipitation, reporter assays, mutant E1A constructs Journal of virology Medium 21715488
2013 Somatic missense, nonsense, and frameshift mutations in DP-1 (TFDP1) are identified in human tumors. Most mutations leave dimerization intact but alter DNA binding, transcriptional activation, and pRb-binding properties of the E2F-1/DP-1 heterodimer via a transdominant mechanism; many mutants impair E2F-1-dependent apoptosis. Genomic database mining, functional assays (DNA binding, transcription, pRb binding, apoptosis) with mutant DP-1 constructs Oncogene Medium 23934193
2016 COMMD9 physically interacts with TFDP1 through its COMM domain, requiring the DNA-binding domain of TFDP1 for this interaction. COMMD9 promotes TFDP1/E2F1 transcriptional activity; knockdown of COMMD9 attenuates TFDP1/E2F1 activation, arrests the cell cycle at G1/S, and inhibits proliferation in NSCLC cells. Co-immunoprecipitation, siRNA knockdown, reporter assays, cell cycle analysis Cellular signalling Medium 27871936
2016 E2F1 and TFDP1 form a complex that directly regulates PITX1 transcription in articular chondrocytes. TFDP1 knockdown inhibits the activating effect of E2F1 and reduces both PITX1 promoter activity and mRNA transcription. ChIP assays confirmed direct E2F1-PITX1 promoter binding. Luciferase reporter assay, chromatin immunoprecipitation, siRNA knockdown, DNA pulldown PloS one Medium 27802335
2019 KPNA2 (karyopherin α2) mediates nuclear import of E2F1 and TFDP1. Upon KPNA2 knockdown, E2F1 and TFDP1 are retained in the cytoplasm, resulting in reduced STMN1 (stathmin) expression, decreased tumor cell migration, and reduced colony formation in HCC cells. Co-immunoprecipitation, subcellular fractionation, ChIP, quantitative proteomics (LC-MS/MS), siRNA knockdown, colony formation assay Cell communication and signaling : CCS Medium 31783876
2022 KDM6B (an H3K27me3 demethylase) specifically interacts with TFDP1 to activate Trp53 expression in palatal mesenchymal cells. Without KDM6B, TFDP1 cannot activate Trp53 expression. KDM6B antagonistically controls H3K27me3 on the Trp53 promoter with EZH2; TFDP1 normally binds the Trp53 promoter. Conditional knockout mouse model, ChIP, reporter assays, co-immunoprecipitation eLife Medium 35212626
2023 The TFDP1 gene is a transcriptional target of deregulated E2F1. Overexpression of E2F1 and forced pRb inactivation (by adenovirus E1a) induces TFDP1 gene expression. GC-rich elements in the TFDP1 promoter bind deregulated (but not physiological) E2F1 as shown by ChIP. DP-1 knockdown enhances ARF expression (a deregulated E2F target), suggesting a failsafe feedback mechanism. Reporter assay (promoter deletion and point mutation analysis), ChIP, shRNA knockdown, adenovirus E1a overexpression Biochemical and biophysical research communications Medium 37141667
2024 TFDP1 modulates global chromatin accessibility through transcriptional regulation of canonical histones. CRISPR knockout of TFDP1 revealed distinct and specific effects on chromatin accessibility genome-wide. Genome-wide CRISPR screen combined with ATAC-see, ATAC-seq, TFDP1 knockout Nature genetics High 38361031
2024 TFDP1 is essential for HSPC proliferation and post-transplant hematopoiesis. E2F4 serves as a binding partner of TFDP1 in HSPCs, and deletion of TFDP1 causes downregulation of cell cycle genes, approximately 50% of which are direct targets of TFDP1 and E2F4. In vivo CRISPR/Cas9-based genetic screen, bone marrow transplantation, gene expression analysis, ChIP (direct target identification) Leukemia High 39043964
2021 An E2F5-TFDP1-BRG1 complex mediates transcriptional activation of MYCN in hepatocytes during liver regeneration. BRG1 is recruited by E2F5/TFDP1 to the MYCN promoter and regulates histone H3 acetylation and H3K4 trimethylation to facilitate RNA polymerase II binding. RNA interference, ChIP, co-immunoprecipitation, qPCR, Western blotting Frontiers in cell and developmental biology Medium 34746136
2002 Antisense oligonucleotide-mediated downregulation of TFDP1 in HCC cells led to downregulation of CCNE1, indicating that TFDP1 overexpression drives upregulation of CCNE1 (a positive regulator of G1/S transition). Antisense oligonucleotide knockdown, quantitative real-time PCR Hepatology (Baltimore, Md.) Low 12029633
2003 Antisense-mediated down-regulation of TFDP1 in Hep3B HCC cells (which overexpress TFDP1) inhibited cell growth, and expression of TFDP1 and E2F1 correlated with expression of seven transcriptional targets (TYMS, DHFR, PCNA, RRM1, CCNE1, CDC2, MYBL2) playing roles in G1/S transition. Antisense oligonucleotide knockdown, quantitative real-time RT-PCR, cell growth assay Journal of human genetics Low 14618416
2015 Positional cloning of the medaka kyoho mutant identified TFDP1 as the causative gene; loss of TFDP1 leads to S-phase arrest and higher polyploidization of erythrocytes, resulting in abnormally large erythrocytes with altered karyotype during development. Positional cloning, phenotypic analysis of mutant fish, cell cycle analysis Developmental dynamics Medium 25648602
2014 A recurrent frameshift indel mutation (indel84) in TFDP1 found in 70% of colorectal cancers generates an alternative TFDP1 protein missing the first 120 amino acids (including the DNA-binding domain) and confers a gain-of-function phenotype: increased cell proliferation, migration, and invasion of CRC cells. Next-generation sequencing, functional assays (proliferation, migration, invasion) with mutant TFDP1 Omics : a journal of integrative biology Medium 25133581
2023 TFDP1 transcriptionally activates TK1 (thymidine kinase 1) in cervical cancer cells by directly binding to the TK1 promoter. TFDP1 knockdown suppresses TK1 expression and reduces cervical cancer cell proliferation, EMT, migration, and invasion, and TK1 overexpression rescues the suppressive effects of TFDP1 knockdown. Chromatin immunoprecipitation, dual-luciferase reporter assay, siRNA knockdown, rescue experiments, xenograft Functional & integrative genomics Medium 37715794
2024 TFDP1 transcriptionally activates SPC25, and TFDP1-SPC25 signaling promotes glutamine metabolism in lung adenocarcinoma cells to suppress NK cell anti-tumor immunity. ChIP and luciferase reporter assays confirmed TFDP1 as a direct transcriptional activator of SPC25. Luciferase reporter assay, ChIP, flow cytometry, LDH cytotoxicity assay, ELISA Expert review of clinical immunology Low 40552366
2025 TFDP1 inhibits cellular senescence in TNBC cells; its knockdown inhibits cell growth, clonal expansion, and tumorigenicity. Topotecan inhibits TNBC cell growth and promotes senescence, counteracting the effects of TFDP1 overexpression, suggesting TFDP1 is a functional target of topotecan. CRISPR/Cas9 library screen, knockdown, overexpression, senescence assays, cell growth assays, xenograft International journal of biological macromolecules Low 40300683

Source papers

Stage 0 corpus · 86 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1993 Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes & development 470 8405995
1994 DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends in biochemical sciences 349 8203017
1994 Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Molecular and cellular biology 263 7969176
2016 Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis. Journal of hepatology 258 26812074
1993 A new component of the transcription factor DRTF1/E2F. Nature 256 8446173
1993 Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F. The EMBO journal 248 8223441
2002 TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology (Baltimore, Md.) 162 12029633
1995 E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Molecular and cellular biology 156 8524253
2007 The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. British journal of pharmacology 134 17965752
1996 Expression of dominant-negative mutant DP-1 blocks cell cycle progression in G1. Molecular and cellular biology 123 8668186
2001 TRIP-Br: a novel family of PHD zinc finger- and bromodomain-interacting proteins that regulate the transcriptional activity of E2F-1/DP-1. The EMBO journal 103 11331592
1994 DP-1: a cell cycle-regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein. The EMBO journal 96 8039504
2009 Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. Breast cancer research : BCR 81 19995430
1997 The lytic enzyme of the pneumococcal phage Dp-1: a chimeric lysin of intergeneric origin. Molecular microbiology 70 9379901
1997 Inhibition of E2F-4/DP-1-stimulated transcription by p202. Oncogene 65 9233764
1996 The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 58 8780882
1995 A new member of the DP family, DP-3, with distinct protein products suggests a regulatory role for alternative splicing in the cell cycle transcription factor DRTF1/E2F. Oncogene 57 7478568
1994 Heterodimerization of the transcription factors E2F-1 and DP-1 is required for binding to the adenovirus E4 (ORF6/7) protein. Journal of virology 54 8035503
1996 Functional interaction between DP-1 and p53. Molecular and cellular biology 53 8816502
2020 miR-4711-5p regulates cancer stemness and cell cycle progression via KLF5, MDM2 and TFDP1 in colon cancer cells. British journal of cancer 52 32066912
2016 COMMD9 promotes TFDP1/E2F1 transcriptional activity via interaction with TFDP1 in non-small cell lung cancer. Cellular signalling 51 27871936
2003 Association of over-expressed TFDP1 with progression of hepatocellular carcinomas. Journal of human genetics 50 14618416
2010 Genome annotation and intraviral interactome for the Streptococcus pneumoniae virulent phage Dp-1. Journal of bacteriology 46 21097633
2011 Adenovirus E1A directly targets the E2F/DP-1 complex. Journal of virology 42 21715488
2019 Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer. Cell communication and signaling : CCS 35 31783876
2019 Long noncoding RNA lnc-DILC stabilizes PTEN and suppresses clear cell renal cell carcinoma progression. Cell & bioscience 34 31592114
2019 LncRNA DILC participates in rheumatoid arthritis by inducing apoptosis of fibroblast-like synoviocytes and down-regulating IL-6. Bioscience reports 33 30944206
1995 Functional conservation of the cell cycle-regulating transcription factor DRTF1/E2F and its pathway of control in Drosophila melanogaster. Journal of cell science 33 8537434
2020 Inhibition of lncRNA DILC attenuates neuropathic pain via the SOCS3/JAK2/STAT3 pathway. Bioscience reports 31 32510145
1994 Mutually exclusive interaction of the adenovirus E4-6/7 protein and the retinoblastoma gene product with internal domains of E2F-1 and DP-1. Journal of virology 30 7933066
2019 lncRNA DILC is downregulated in osteoarthritis and regulates IL-6 expression in chondrocytes. Journal of cellular biochemistry 28 31069838
1996 Expression of the E2F-1/DP-1 transcription factor in murine development. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 28 8788032
2018 Long non-coding RNA DILC suppresses cell proliferation and metastasis in colorectal cancer. Gene 27 29621586
2011 Co-operative signalling through DP(1) and DP(2) prostanoid receptors is required to enhance leukotriene C(4) synthesis induced by prostaglandin D(2) in eosinophils. British journal of pharmacology 24 20973774
2004 The DP-1 transcription factor is required for keratinocyte growth and epidermal stratification. The Journal of biological chemistry 24 15448153
1984 Biochemical characterization of a murein hydrolase induced by bacteriophage Dp-1 in Streptococcus pneumoniae: comparative study between bacteriophage-associated lysin and the host amidase. Journal of bacteriology 24 6146601
2008 Central prostaglandin D(2) exhibits anxiolytic-like activity via the DP(1) receptor in mice. Prostaglandins & other lipid mediators 23 19007903
1983 A phage-associated murein hydrolase in Streptococcus pneumoniae infected with bacteriophage Dp-1. Journal of general microbiology 23 6132961
2005 Identification and characterization of novel isoforms of human DP-1: DP-1{alpha} regulates the transcriptional activity of E2F1 as well as cell cycle progression in a dominant-negative manner. The Journal of biological chemistry 22 15863509
1999 Association with E2F-1 governs intracellular trafficking and polyubiquitination of DP-1. Oncogene 22 9989809
2024 Genome-wide ATAC-see screening identifies TFDP1 as a modulator of global chromatin accessibility. Nature genetics 20 38361031
2019 Long non-coding RNA DILC promotes the progression of gallbladder carcinoma. Gene 20 30716440
2016 E2F1 and TFDP1 Regulate PITX1 Expression in Normal and Osteoarthritic Articular Chondrocytes. PloS one 20 27802335
2008 SOCS-3 inhibits E2F/DP-1 transcriptional activity and cell cycle progression via interaction with DP-1. The Journal of biological chemistry 20 18687693
1993 Regulation of adenovirus 12 E1A transcription: E2F and ATF motifs in the E1A promoter bind nuclear protein complexes including E2F1, DP-1, cyclin A and/or RB and mediate transcriptional (auto)activation. Cellular & molecular biology research 20 7951410
2023 The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F. Biochemical and biophysical research communications 19 37141667
2000 Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex. Clinical cancer research : an official journal of the American Association for Cancer Research 19 10778981
2018 Long non‑coding RNA DILC is involved in sepsis by modulating the signaling pathway of the interleukin‑6/signal transducer and activator of transcription 3/Toll‑like receptor 4 axis. Molecular medicine reports 18 30365067
2022 KDM6B interacts with TFDP1 to activate P53 signaling in regulating mouse palatogenesis. eLife 17 35212626
2021 Protectin DX promotes the inflammatory resolution via activating COX-2/L-PGDS-PGD2 and DP1 receptor in acute respiratory distress syndrome. International immunopharmacology 17 34920958
1997 The predominant E2F complex in human primary haemopoietic cells and in AML blasts contains E2F-4, DP-1 and p130. British journal of haematology 17 9074408
2000 Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents. Cancer chemotherapy and pharmacology 15 11052627
2021 An E2F5-TFDP1-BRG1 Complex Mediates Transcriptional Activation of MYCN in Hepatocytes. Frontiers in cell and developmental biology 14 34746136
2013 Dystonia, facial dysmorphism, intellectual disability and breast cancer associated with a chromosome 13q34 duplication and overexpression of TFDP1: case report. BMC medical genetics 14 23849371
2022 Effect of Upregulation of Transcription Factor TFDP1 Binding Promoter Activity Due to RBP4 g.36491960G>C Mutation on the Proliferation of Goat Granulosa Cells. Cells 12 35883591
2002 Immunohistochemical expression of the transcription factor DP-1 and its heterodimeric partner E2F-1 in non-Hodgkin lymphoma. Applied immunohistochemistry & molecular morphology : AIMM 12 12607600
2019 Long non-coding RNA DILC suppresses bladder cancer cells progression. Gene 11 31176734
2014 Next-generation sequencing of colorectal cancers in chinese: identification of a recurrent frame-shift and gain-of-function Indel mutation in the TFDP1 gene. Omics : a journal of integrative biology 11 25133581
2000 Upregulation of a raf kinase and a DP-1 family transcription factor in epidermal growth factor (EGF) stimulated filarial parasites. International journal for parasitology 11 10996327
1992 Cyclin A recruits p33cdk2 to the cellular transcription factor DRTF1. Journal of cell science. Supplement 11 1297652
2013 Pleiotropic effect of somatic mutations in the E2F subunit DP-1 gene in human cancer. Oncogene 10 23934193
2003 Loss of protein phosphatase 2A expression correlates with phosphorylation of DP-1 and reversal of dysplasia through differentiation in a conditional mouse model of cancer progression. Cancer research 10 14633688
2024 ZNF146 regulates cell cycle progression via TFDP1 and DEPDC1B in ovarian cancer cells. Reproduction (Cambridge, England) 8 38614125
2019 Expression of the TFDP1 gene in the endometrium of women with deep infiltrating endometriosis. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 7 30638096
2016 Prostaglandin D2 effects and DP1 /DP2 receptor distribution in guinea pig urinary bladder out-flow region. Journal of cellular and molecular medicine 7 27664012
2024 In vivo CRISPR/Cas9-mediated screen reveals a critical function of TFDP1 and E2F4 transcription factors in hematopoiesis. Leukemia 6 39043964
2021 Prostaglandin D2 inhibits mediator release and antigen induced bronchoconstriction in the Guinea pig trachea by activation of DP1 receptors. European journal of pharmacology 6 34175307
2023 Transcription factor Dp-1 knockdown downregulates thymidine kinase 1 expression to protect against proliferation and epithelial-mesenchymal transition in cervical cancer. Functional & integrative genomics 5 37715794
2025 Developing a risk assessment model for treatment-resistant schizophrenia: The role of niacin receptor GPR109A and prostaglandin receptors DP1, EP2, and EP4 in the niacin-induced flushing pathway. Schizophrenia research 4 40220605
2023 Comprehensive Analysis Reveals the Potential Roles of Transcription Factor Dp-1 in Lung Adenocarcinoma. World journal of oncology 4 37350808
2022 U2 small nuclear RNA auxiliary factor 2, transcriptionally activated by the transcription factor Dp-1/E2F transcription factor 1 complex, enhances the growth and aerobic glycolysis of leiomyosarcoma cells. Bioengineered 4 35502531
2010 Identification of significant regions of transcription factor DP-1 (TFDP-1) involved in stability/instability of the protein. Biochemical and biophysical research communications 4 20513349
2025 TFDP1 drives triple-negative breast Cancer development through senescence suppression and serves as a therapeutic target for topotecan. International journal of biological macromolecules 3 40300683
2025 TFDP1 activates SPC25-mediated glutamine metabolism to repress anti-tumor immunity of NK cells in lung adenocarcinoma. Expert review of clinical immunology 3 40552366
2018 Hypoactivity of rat detrusor muscle in a model of cystitis: exacerbation by non-selective COX inhibitors and amelioration by a selective DP1 receptor antagonist. Naunyn-Schmiedeberg's archives of pharmacology 3 30552456
2024 CKAP2 Regulated by TFDP1 Promotes Metastasis and Proliferation of Colorectal Cancer through Affecting the Tumor Microenvironment. Journal of microbiology and biotechnology 2 39403723
2023 Structural Analyses of DP-1, a Protein with the Ability To Bind Gold Nanoparticles, by Using Nuclear Magnetic Resonance Spectroscopy. Chembiochem : a European journal of chemical biology 2 37792876
2015 Proliferation following tetraploidization regulates the size and number of erythrocytes in the blood flow during medaka development, as revealed by the abnormal karyotype of erythrocytes in the medaka TFDP1 mutant. Developmental dynamics : an official publication of the American Association of Anatomists 2 25648602
2023 Dispersion Function of a Protein, DP-1, Identified in Collimonas sp. D-25, for the Synthesis of Gold Nanoparticles. Chembiochem : a European journal of chemical biology 1 37232370
2019 Sustained exposure to prostaglandin D2 augments the contraction induced by acetylcholine via a DP1 receptor-mediated activation of p38 in bronchial smooth muscle of naive mice. Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi 1 30918168
2026 E2F2 and TFDP1 as novel systemic lupus erythematosus (SLE) diagnostic markers and therapeutic targets based on machine learning and experimental study. Hereditas 0 42108498
2025 TFDP1 overexpression promotes apoptosis of nucleus pulposus cells in intervertebral disc degeneration through regulating ADAM15/MMP9 axis. General physiology and biophysics 0 39815900
2025 Upregulation of TFDP1 and CDC27 Plays an Important Role in Bronchiectasis. Canadian respiratory journal 0 41458288
2016 Correction: E2F1 and TFDP1 Regulate PITX1 Expression in Normal and Osteoarthritic Articular Chondrocytes. PloS one 0 27880827
2008 [Preparation of the polypeptide antibody against human transcriptional factors TFDP1 and TFDP3]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 0 18782520
1985 [Phenotypical curing of Streptococcus pneumoniae treated with amidase induced by the Dp-1 bacteriophage]. Microbiologia (Madrid, Spain) 0 2908322

Missed literature

Know a paper Affinage missed for TFDP1? Flag it for the maintainers and the community.

No submissions yet.